Zimmer Biomet shares drop almost 4% after reversing from early gains despite Q3 beat and raised guidance

Zimmer Biomet shares drop almost 4% after reversing from early gains despite Q3 beat and raised guidance
Zimmer biomet slides 3.99% today

Zimmer Biomet Holdings Inc (ZBH) fell 3.99% as price action reversed after an initial positive gap, even as its stronger-than-expected Q3 earnings and raised guidance created a fundamentally positive backdrop. The pullback contradicts the broadly bullish technical structure, with ZBH trading above all major moving averages in a tight corridor.

ZBH price prediction
24H -0.54%
$102.65
48H -0.98%
$102.2
7D -1.01%
$102.17
1M 10.64%
$114.19
3M -0.28%
$102.92
6M 0.84%
$104.08
12M -2.46%
$100.67
Current price: $103.21 -1.4000 1.34%
Closed 11/13
Daily range 102.88 Arrow from to Icon 105.61
Weekly range 102.88 Arrow from to Icon 109.29
Loading...

Highlights

  • Zimmer Biomet reported Q3 2026 net sales of $2.063 billion, a 3.1% year-over-year increase with adjusted EPS of $1.90.
  • GAAP diluted EPS declined 13.8% on higher expenses and softness in the knee segment, but management raised full-year sales growth and adjusted EPS guidance.
  • Zimmer Biomet stock trades near its session low after an initial gap up, with technical indicators suggesting ongoing strength but overbought conditions and a projected five-day range of $96.75 to $114.77.

Mixed growth offsets knee weakness as guidance and highs meet selling

Zimmer Biomet reported Q3 2026 net sales of $2.063 billion, representing a 3.1% rise year-over-year. Adjusted earnings per share were $1.90, slightly ahead of analyst forecasts, while GAAP diluted EPS fell 13.8% due to increased expenses and softness in the knee segment. Growth in hips, S.E.T., and technology helped offset knee declines, and management raised both full-year sales growth and adjusted EPS guidance. Free cash flow improved and the stock marked a new 52-week high, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, sees disconnect between Zimmer Biomet’s strong Q3 fundamentals and recent price weakness. He notes technical momentum remains positive, but the overbought reading on multiple indicators signals correction risk. Despite raised guidance, he flags segment-specific softness and reversal from session highs as red flags. Kharitonov views the downside as underpriced by the market given the 3.99% drop despite bullish consensus. He warns, "Short-term pressure could deepen if the price fails to hold above $105.55, so I advise caution rather than chasing the bounce."
Viktoras Karapetjanc, expert at Traders Union, highlights Zimmer Biomet’s healthy sales growth and improved guidance as key positives. He considers management’s outlook upgrades and robust free cash flow as evidence of resilient fundamental momentum. Karapetjanc believes the bullish structure remains intact with strong institutional support observed above major moving averages. He states, "With the upward move highly probable and long-term signals robust, I see further growth opportunities for ZBH in the upcoming sessions."
Sholanke Dele, market strategist, interprets the recent price reversal as a signal of fading market confidence despite positive results. He cautions that the overbought technical indicators pose near-term risk. Dele notes the volatility spike and loss of session highs may attract more short sellers. He concludes, "Sustained weakness below resistance could see ZBH drift toward $105.55 or lower if sentiment turns defensive."
Zimmer Biomet Holdings Inc asset chart
Zimmer Biomet Holdings Inc price dynamics. Source: TradingView.

Overbought signals flag correction risk as momentum retreats intraday

Zimmer Biomet is positioned above its 20-day, 50-day, and 200-day moving averages at $95.65, $94.9, and $91.84, confirming a bullish structure across short-, medium-, and long-term horizons. Immediate technical resistance stands at $111, with key support at $105.55, delineating a narrow trading range. Momentum remains strong, as MACD and ADX both register buy signals. RSI, Stochastic RSI, and CCI are all in the overbought zone, signaling heightened risk of a short-term correction or overheating. The Bull/Bear Power is positive at 14.57, highlighting buyer dominance in intraday action. The Awesome Oscillator backs the ongoing buying trend. Recent trading saw a reversal lower toward session lows despite an earlier upside gap, with volatility marked at 5.16%. Upward momentum has come under pressure after the open, indicating retreat from intraday highs, even as long-term signals remain constructive.

Previously it was reported that Zimmer Biomet’s bullish chart structure and earnings-driven momentum indicated strong potential for further upside. The current article adds a new dimension by highlighting the possibility of heightened volatility despite robust fundamentals, with immediate attention on the $111 resistance level as a potential catalyst for the next directional move.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.